| Market Cap | 42.18M | P/E | - | EPS this Y | -2.50% | Ern Qtrly Grth | - |
| Income | -37.57M | Forward P/E | -1.49 | EPS next Y | 8.10% | 50D Avg Chg | 12.00% |
| Sales | 9.14M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -38.00% |
| Dividend | N/A | Price/Book | 0.38 | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | 3.00 | Quick Ratio | 8.56 | Shares Outstanding | 31.91M | 52W Low Chg | 41.00% |
| Insider Own | 5.40% | ROA | -25.00% | Shares Float | 30.19M | Beta | -0.86 |
| Inst Own | 14.74% | ROE | -42.73% | Shares Shorted/Prior | 225.78K/300.94K | Price | 1.37 |
| Gross Margin | 59.83% | Profit Margin | - | Avg. Volume | 126,853 | Target Price | 1.50 |
| Oper. Margin | -289.06% | Earnings Date | Nov 7 | Volume | 71,981 | Change | -2.49% |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Brown Brian Lee | Chief Financial Offi.. Chief Financial Officer | Mar 20 | Buy | 1.899 | 3,000 | 5,697 | 76,236 | 03/21/23 |
| Egan Dwight H | Chief Executive Offi.. Chief Executive Officer | Jan 20 | Option | 2.63 | 50,000 | 131,500 | 50,000 | 01/20/21 |
| Egan Dwight H | Chief Executive Offi.. Chief Executive Officer | Jan 20 | Sell | 11 | 38,046 | 418,506 | 01/20/21 | |
| Egan Dwight H | Chief Executive Offi.. Chief Executive Officer | Nov 25 | Option | 1.1 | 150,000 | 165,000 | 50,000 | 11/25/20 |
| Egan Dwight H | Chief Executive Offi.. Chief Executive Officer | Nov 25 | Sell | 10.68 | 134,350 | 1,434,858 | 11/25/20 |